The Impact of Pandemic Influenza H1N1 on Health-related Quality of Life: a Prospective Population-based Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Mar 15

PMID 21399678

Citations 42

Authors

Albert Jan van Hoek

Anthony Underwood

Mark Jit

Elizabeth Miller

W John Edmunds

Affiliations

Soon will be listed here.

Abstract

Background: While the H1N1v influenza pandemic in 2009 was clinically mild, with a low case-fatality rate, the overall disease burden measured in quality-adjusted life years (QALY) lost has not been estimated. Such a measure would allow comparison with other diseases and assessment of the cost-effectiveness of pandemic control measures.

Methods And Findings: Cases of H1N1v confirmed by polymerase chain reaction (PCR) and PCR negative cases with similar influenza-like illness (ILI controls) in 7 regions of England were sent two questionnaires, one within a week of symptom onset and one two weeks later, requesting information on duration of illness, work loss and antiviral use together with EQ-5D questionnaires. Results were compared with those for seasonal influenza from a systematic literature review. A total QALY loss for the 2009 pandemic in England was calculated based on the estimated total clinical cases and reported deaths. A total of 655 questionnaires were sent and 296 (45%) returned. Symptoms and average illness duration were similar between confirmed cases and ILI controls (8.8 days and 8.7 days respectively). Days off work were greater for cases than ILI controls (7.3 and 4.9 days respectively, p = 0.003). The quality-adjusted life days lost was 2.92 for confirmed cases and 2.74 for ILI controls, with a reduction in QALY loss after prompt use of antivirals in confirmed cases. The overall QALY loss in the pandemic was estimated at 28,126 QALYs (22,267 discounted) of which 40% was due to deaths (24% with discounting).

Conclusion: Given the global public health significance of influenza, it is remarkable that no previous prospective study of the QALY loss of influenza using standardised and well validated methods has been performed. Although the QALY loss was minor for individual patients, the estimated total burden of influenza over the pandemic was substantial when compared to other infectious diseases.

Citing Articles

Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model.

Pritchard C, Kutikova L, Pitman R, Lai K, Beyhaghi H, Gibbons I Vaccines (Basel). 2025; 13(2).

PMID: 40006733 PMC: 11861217. DOI: 10.3390/vaccines13020187.

The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022).

Willem L, Abrams S, Franco N, Coletti P, Libin P, Wambua J BMC Public Health. 2024; 24(1):1171.

PMID: 38671366 PMC: 11047051. DOI: 10.1186/s12889-024-18576-w.

Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.

Sahota O, Narayanasamy M, Bastounis A, Paskins Z, Bishop S, Langley T Health Technol Assess. 2024; 28(21):1-169.

PMID: 38634483 PMC: 11056815. DOI: 10.3310/WYPF0472.

Understanding the impact of adult pertussis and current approaches to vaccination: A narrative review and expert panel recommendations.

Kardos P, Correia de Sousa J, Heininger U, Konstantopoulos A, MacIntyre C, Middleton D Hum Vaccin Immunother. 2024; 20(1):2324547.

PMID: 38564339 PMC: 10989709. DOI: 10.1080/21645515.2024.2324547.

Physical health and mental health functional status during and following hospitalization for an acute respiratory illness.

Nowalk M, Balasubramani G, Sax T, Eng H, Saul S, Susick M Brain Behav Immun Health. 2024; 1:100004.

PMID: 38377430 PMC: 8474592. DOI: 10.1016/j.bbih.2019.100004.

References

Sander B, Hayden F, Gyldmark M, Garrison Jr L . Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics. 2006; 24(4):373-86. DOI: 10.2165/00019053-200624040-00007. View

Siddiqui M, Edmunds W . Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg Infect Dis. 2008; 14(2):267-74. PMC: 2600182. DOI: 10.3201/eid1402.070478. View

Wailoo A, Sutton A, Cooper N, Turner D, Abrams K, Brennan A . Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. Value Health. 2008; 11(2):160-71. DOI: 10.1111/j.1524-4733.2007.00241.x. View

Nishiura H . The virulence of pandemic influenza A (H1N1) 2009: an epidemiological perspective on the case-fatality ratio. Expert Rev Respir Med. 2010; 4(3):329-38. DOI: 10.1586/ers.10.24. View

Li I, Hung I, To K, Chan K, Wong S, Chan J . The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest. 2010; 137(4):759-68. PMC: 7094292. DOI: 10.1378/chest.09-3072. View

Prosser L, Bridges C, Uyeki T, Hinrichsen V, Meltzer M, Molinari N . Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis. 2006; 12(10):1548-58. PMC: 3290928. DOI: 10.3201/eid1210.051015. View

Carrat F, Vergu E, Ferguson N, Lemaitre M, Cauchemez S, Leach S . Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008; 167(7):775-85. DOI: 10.1093/aje/kwm375. View

Griffin A, Perry A, Fleming D . Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics. 2001; 19(3):293-301. DOI: 10.2165/00019053-200119030-00007. View

Ellis J, Iturriza M, Allen R, Bermingham A, Brown K, Gray J . Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses. Euro Surveill. 2009; 14(22). DOI: 10.2807/ese.14.22.19230-en. View

10.

Prosser L, Bridges C, Uyeki T, Rego V, Ray G, Meltzer M . Values for preventing influenza-related morbidity and vaccine adverse events in children. Health Qual Life Outcomes. 2005; 3:18. PMC: 1083419. DOI: 10.1186/1477-7525-3-18. View

11.

Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N . Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010; 19(6):875-86. PMC: 2892611. DOI: 10.1007/s11136-010-9648-y. View

12.

Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K . Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003; 7(35):iii-iv, xi-xiii, 1-170. DOI: 10.3310/hta7350. View

13.

Cowling B, Chan K, Fang V, Lau L, So H, Fung R . Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med. 2010; 362(23):2175-2184. PMC: 4070281. DOI: 10.1056/NEJMoa0911530. View

14.

Kind P, Dolan P, Gudex C, Williams A . Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998; 316(7133):736-41. PMC: 28477. DOI: 10.1136/bmj.316.7133.736. View

15.

Pebody R, McLean E, Zhao H, Cleary P, Bracebridge S, Foster K . Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. Euro Surveill. 2010; 15(20). View

16.

Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M . Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010; 375(9720):1100-8. DOI: 10.1016/S0140-6736(09)62126-7. View

17.

Brisson M, Edmunds W . Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child. 2003; 88(10):862-9. PMC: 1719324. DOI: 10.1136/adc.88.10.862. View

18.

Rothberg M, Bellantonio S, Rose D . Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med. 2003; 139(5 Pt 1):321-9. DOI: 10.7326/0003-4819-139-5_part_1-200309020-00007. View

19.

OBrien B, Goeree R, Blackhouse G, Smieja M, Loeb M . Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. Value Health. 2003; 6(2):116-25. DOI: 10.1046/j.1524-4733.2003.00213.x. View

20.

Sander B, Kwong J, Bauch C, Maetzel A, McGeer A, Raboud J . Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med. 2010; 7(4):e1000256. PMC: 2850382. DOI: 10.1371/journal.pmed.1000256. View